register

Digital & Innovation

IDE Group and Kipuwex to develop next-gen telehealth solutions for remote patient care

Health Industry Hub | April 28, 2021 |

Digital & Innovation: Australian consultancy and venture builder delivering medtech innovations, IDE Group, and Kipuwex, a Finnish technology company, announced their strategic partnership in developing and bringing innovative telehealth solutions to healthcare providers and customers globally.

The demand for healthcare services and technologies reached an all-time high in the wake of the COVID-19 pandemic. The potential of telehealth has been emphasised given a global shortage in hospital beds and healthcare workers, creating a once in a generation opportunity to modernise healthcare systems around the world. The telehealth market size is valued at US$49.8 billion and will increase to US$266.8 billion in 2026, with a CAGR of 23.4%.

The Kipuwex-IDE Group partnership will build on Kipuwex’s easily attachable, light weight Internet of Medical Things (IoMT) device which wirelessly and continuously measures clinically relevant biomarkers vital to the assessment of human well-being and disease management to facilitate real-time data collection, improve remote patient care, enhance clinical workflows and increase healthcare provider efficiency.

IDE Group’s entrepreneurial partnership will help Kipuwex develop and commercialise a differentiated telehealth offering delivering meaningful healthcare outcomes in Europe, the Asia Pacific region and globally.
“In today’s competitive environment, collaboration is the enabler for the success of the company. Through collaboration with IDE Group we can achieve a common goal, which is to improve healthcare worldwide by providing reliable and affordable telehealth solutions,” said Kipuwex CEO Marko Höynälä.

“This collaboration provides IDE Group with a great opportunity to bring its entrepreneurial values, MedTech hardware design & development expertise, and proven track record in creating value in new ventures, together with Kipuwex’s exciting portfolio of product, telehealth expertise and deep in-market relationships to improve healthcare outcomes worldwide,” added IDE Group Managing Director George Sidis.

This partnership aligns with IDE Group’s strategic pillars. “There are four main areas where we partner and invest in based on our expertise; wearable therapeutic and diagnostic monitoring devices, drug delivery, surgical instruments, and diagnostics. This collaboration aligns with our particular knowledge and expertise to add value,” noted Mr Sidis. 

Kipuwex and IDE Group expect to launch their innovative telehealth offering in the next two to three years.

You may also like Sanofi’s new Sydney office purpose built for agile, inclusive and hybrid working environment


News & Trends - Biotechnology

AusBiotech appoints new CEO: Former Sanofi corporate affairs and sustainability leader takes the helm

AusBiotech appoints new CEO: Former Sanofi corporate affairs and sustainability leader takes the helm

Health Industry Hub | April 23, 2024 |

Biotech News: AusBiotech, the nation’s leading industry body for the biotech sector, has named former leader at Sanofi, Rebekah Cassidy, […]

More


News & Trends - MedTech & Diagnostics

Federal government invests in Siemens Healthineers scanner to 'reduce wait times' for cancer diagnosis

Federal government invests in Siemens Healthineers scanner to ‘reduce wait times’ for cancer diagnosis

Health Industry Hub | April 23, 2024 |

MedTech & Diagnostics News: The Albanese Government is investing $12 million through the 2024–25 Budget, to purchase and install a […]

More


News & Trends - MedTech & Diagnostics

Cardiac device benefits face more cuts, while technical services remain secure in the short term

Cardiac device benefits face more cuts, while technical services remain secure in the short term

Health Industry Hub | April 23, 2024 |

MedTech & Diagnostics News: Starting from July 2024, Cardiac Implantable Electronic Devices (CIED) listed on the Prescribed List (PL) will […]

More


News & Trends - Biotechnology

CSL's world-first gene therapy heads for MSAC assessment

CSL’s world-first gene therapy heads for MSAC evaluation

Health Industry Hub | April 23, 2024 |

Biotech News: CSL’s world-first gene therapy for haemophilia B is scheduled for consideration at the upcoming Medical Services Advisory Committee (MSAC) […]

More


This content is copyright protected. Please subscribe to gain access.